CompletedNot Applicable

The Prognostic Role of Red Blood Cell Distribution (RDW) in Severe COVID-19 Patients

Turkey (Türkiye)146 participantsStarted 2024-09-01

Plain-language summary

The aim of this study was to evaluate the prognostic significance of erythrocyte distribution width (RDW) in severe and critically ill COVID-19 patients followed in the intensive care unit (ICU). RDW is a parameter that measures the heterogeneity in red blood cell size and is associated with the pathophysiological processes of COVID-19, such as systemic inflammation, oxidative stress, and erythropoiesis disorders. This study investigated the relationship between RDW and the need for intubation and mortality, and its utility as a prognostic marker in COVID-19 patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18 years and older * Severe and critically ill COVID-19 patients (PCR test positivity of COVID) * Patients who have been monitored in the intensive care unit for at least 3 days * Patients without haematological malignancies Exclusion Criteria: * Patients under 18 years of age * Those with haematological malignancies (as this may affect RDW levels) * Patients who died within 3 days of admission to intensive care

What they're measuring

discharge / death

Timeframe: From admission to the intensive care unit until ICU discharge or death, assessed up to 30 days.

Trial details

NCT IDNCT07244731

SponsorAnkara University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More COVID - 19 trials